Statistics

Total Visits

Views
Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy53

Select a period of time:

Number of views in the range

Views
Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy42

Views

Views
February 20250
March 202515
April 20252
May 20251
June 20251
July 202522
August 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
Brazil10
United States7
Venezuela2
United Kingdom2
Canada1
Spain1
France1
Hungary1
Italy1
 

Top cities views

Views
Caracas1
Clermont-Ferrand1
Council Bluffs1
Crestline1
Embu das Artes1
Exeter1
Florianópolis1
Gastonia1
Hazard1
London1